Literature DB >> 29662931

Ulcerative Colitis: Are We Neglecting Its Progressive Character.

Paulo Massinha1, Francisco Portela1, Sara Campos1, Gabriela Duque2, Manuela Ferreira1, Sofia Mendes1, Ana Margarida Ferreira1, Carlos Sofia1, Luís Tomé1.   

Abstract

INTRODUCTION: Ulcerative colitis (UC) is a chronic disease but its progressive character, with structural damage, is insufficiently studied.
OBJECTIVES: To analyze a group of patients without referral bias, regarding its clinical course, the morphological damage, and functional status.
METHODS: We evaluated UC patients diagnosed between January 1, 2000 and December 31, 2004, living in the direct referral area of the hospital and determined the medication use, colectomy rate, structural damage ("lead pipe," stenosis, pseudopolyps, fibrous bridges), and anorectal function (prospective evaluation with the Cleveland Clinic Incontinence Score [CCIS] and the Fecal Incontinence Quality of Life Scale).
RESULTS: We identified 104 patients, 47% female, with a mean age at diagnosis of 38 ± 17 years, 24% with proctitis, 57% with left colitis, and 19% with pancolitis. In 3 patients, it was not possible to obtain follow-up data. Of the studied patients, 56% needed corticosteroid therapy, 38% immunosuppressants, and 16% anti-tumor necrosis factors (anti-TNFs). After a mean follow-up of 13 ± 2 years, we found structural damage in 25 patients (24%): 5% with proctocolectomy, 15% with "lead pipe," 16% with pseudopolyps, and 3% with stenosis and fibrous bridges. Reference to functional anorectal disorders was identified in 49%, mostly previous and self-limited episodes of incontinence, but including persistent incontinence in 10% (CCIS 8 ± 4.8). There was an increased incidence of structural damage and anorectal dysfunction in patients who needed corticosteroid therapy (p = 0.001), immunosuppressants (p < 0.001), and anti-TNFs (p = 0.002) and an association of structural damage with anorectal dysfunction (p < 0.001). There was no association between age and anorectal dysfunction, including incontinence episodes.
CONCLUSIONS: UC is a disease with structural and functional consequences in a significant subset of patients. This should be incorporated when defining the therapeutic strategy.

Entities:  

Keywords:  Colon; Disease progression; Inflammatory bowel disease; Prognosis; Ulcerative colitis

Year:  2017        PMID: 29662931      PMCID: PMC5892362          DOI: 10.1159/000481263

Source DB:  PubMed          Journal:  GE Port J Gastroenterol        ISSN: 2387-1954


  25 in total

1.  THE COURSE AND PROGNOSIS OF ULCERATIVE COLITIS. III. COMPLICATIONS.

Authors:  F C EDWARDS; S C TRUELOVE
Journal:  Gut       Date:  1964-02       Impact factor: 23.059

2.  Obstructing giant post-inflammatory polyposis in ulcerative colitis: Case report and review of the literature.

Authors:  James R L Maggs; Lisa C Browning; Bryan F Warren; Simon P L Travis
Journal:  J Crohns Colitis       Date:  2008-01-28       Impact factor: 9.071

3.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.

Authors:  Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren
Journal:  Can J Gastroenterol       Date:  2005-09       Impact factor: 3.522

Review 4.  Current directions in IBD therapy: what goals are feasible with biological modifiers?

Authors:  William J Sandborn
Journal:  Gastroenterology       Date:  2008-10-09       Impact factor: 22.682

5.  Changes in extent of ulcerative colitis: a study on the course and prognostic factors.

Authors:  E Langholz; P Munkholm; M Davidsen; O H Nielsen; V Binder
Journal:  Scand J Gastroenterol       Date:  1996-03       Impact factor: 2.423

Review 6.  Current misunderstandings in the management of ulcerative colitis.

Authors:  Thomas Ochsenkühn; Geert D'Haens
Journal:  Gut       Date:  2011-04-19       Impact factor: 23.059

7.  Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD).

Authors:  S Shivananda; J Lennard-Jones; R Logan; N Fear; A Price; L Carpenter; M van Blankenstein
Journal:  Gut       Date:  1996-11       Impact factor: 23.059

8.  Extension of ulcerative colitis.

Authors:  Canan Alkim; Hüseyin Alkim; Ulkü Dağli; Erkan Parlak; Aysel Ulker; Burhan Sahın
Journal:  Turk J Gastroenterol       Date:  2011-08       Impact factor: 1.852

9.  Generalized giant inflammatory polyposis in a patient with ulcerative colitis presenting with protein-losing enteropathy.

Authors:  H Koga; M Iida; K Aoyagi; T Yao; H Suekane; R Mibu; M Fujishima
Journal:  Am J Gastroenterol       Date:  1995-05       Impact factor: 10.864

10.  Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health.

Authors:  Laurent Peyrin-Biroulet; Alarcos Cieza; William J Sandborn; Michaela Coenen; Yehuda Chowers; Toshifumi Hibi; Nenad Kostanjsek; Gerold Stucki; Jean-Frédéric Colombel
Journal:  Gut       Date:  2011-06-05       Impact factor: 23.059

View more
  2 in total

1.  Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis.

Authors:  Thomas Ochsenkühn; Cornelia Tillack; Daniel Szokodi; Shorena Janelidze; Fabian Schnitzler
Journal:  United European Gastroenterol J       Date:  2019-12-12       Impact factor: 4.623

2.  Long-term follow-up of patients treated with aminosalicylates for ulcerative colitis: Predictive factors of response: An observational case-control study.

Authors:  David Marti-Aguado; María Pilar Ballester; Joan Tosca; Marta Maia Bosca-Watts; Pablo Navarro; Rosario Anton; Isabel Pascual; Francisco Mora; Miguel Minguez
Journal:  United European Gastroenterol J       Date:  2019-05-29       Impact factor: 4.623

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.